MERCANS
22.12.2023 15:10:28 CET | Business Wire | Press release
Avasant, a globally recognized analyst firm, has named Mercans as a payroll process transformation leader in its annual RadarView assessment of 2022-2023. Mercans clearly stood out among the 27 providers assessed for consistently delivering exceptional value to the market. Avasant's comprehensive industry analysis categorizes providers into challengers, disruptors, innovators, and leaders. Avasant placed Mercans in an elite group of industry leaders, confirming its technology leadership role in the global payroll industry.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20231222991924/en/
Mercans Emerges as a Payroll Business Process Transformation Leader in Avasant's RadarView (Photo: AETOSWire)
In a span of one year, Mercans transitioned from a disruptor to an industry leader in Avasant’s assessment, demonstrating its impressive progress across all RadarView’s critical excellence dimensions - practice maturity, domain ecosystem, and investments and innovation.
Avasant's meticulous research methodology, incorporating publicly available information, SEC filings, annual reports, executive interviews, product demos, and direct inputs from service providers, adds depth and credibility to the acknowledgment of Mercans' industry leadership.
Avasant highlights Mercans' strategic approach and states: Leveraging its proprietary payroll engine and in-house local experts, Mercans delivers services across 160 countries. Mercans boasts a distinctive practice size, serving multinational corporations and Fortune 500 companies, supporting over 40 languages. The company's global delivery infrastructure spans 121 local offices, contributing to an impressive payroll revenue growth of over 30% from June 2022 to June 2023, reflecting its financial robustness.
At the heart of Mercans' success lies its proprietary global payroll platform - HR Blizz, the only gross-to-net payroll application that allows generating statutory compliant payrolls worldwide in a single software.
Mercans has disrupted the global payroll landscape with its G2N Nova global payroll engine. This state-of-the-art payroll engine stands out as the sole stateless application globally, swiftly generating payroll calculations across 160 countries within seconds, all while avoiding the storage of any sensitive employee data. This innovative approach has positioned G2N Nova as a catalyst for multinational corporations seeking to fully digitize their global payroll operations. Beyond its uniqueness as the sole global gross-to-net payroll application, G2N Nova offers a fully autonomous and touchless payroll experience, leading to dramatic reductions in processing times and costs.
Aditya Jain, Principal Analyst at Avasant, comments, "Mercans has developed its native global payroll engine to facilitate gross-to-net payroll calculations, digitalize processes, and offer self-service functionality to employees in 160 countries worldwide. Its partnerships with HCM and ancillary HR platform vendors enable it to offer comprehensive HR services through a unified portal. It leverages its local delivery network, including offices and regional experts in 121 countries, to help enterprises reduce dependence on local payroll aggregators for last-mile services across countries.
"Its continued investments in technology innovation, such as no-code HR integration tools and instant payments functionality, flexible business models, and a global delivery network, have made Mercans a leader in Avasant’s Payroll Business Process Transformation 2023–2024 RadarView."
About Mercans
Mercans is a global leader in payroll technology. Mercans’ revolutionary global payroll platform HR Blizz enables SMBs and enterprise businesses to manage payrolls across 160 countries. With 20 years of global payroll expertise, Mercans delivers the full spectrum of HR services through a single, secure global platform.
Visit www.mercans.com
Source: AETOSWire
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20231222991924/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
International Human Rights Lawyer Jared Genser and Former White House Counsel Lanny J. Davis Join Legal and Advocacy Team Supporting Cambodian Businessman Yim Leak, Seiden Law LLP Announces18.9.2026 19:52:00 CEST | Press release
Jared Genser, one of the world's most recognized international human rights lawyers, and Lanny J. Davis, an adviser to former presidents George W. Bush and Bill Clinton, join the legal and advocacy team for Cambodian businessman Yim Leak and challenge what they call a coordinated smear campaign in Thailand. International human rights lawyer Jared Genser and Lanny J. Davis, who has close ties to two former US presidents and a worldwide reputation for defending those under attack with lies and smears, and for repairing the damage done to their reputations, have joined the legal and advocacy team supporting Cambodian businessman Yim Leak, Seiden Law LLP, which serves as Yim Leak's chief global counsel, announced today. Their first move is to hold the Thai government accountable, framing its conduct as either complicit in or willfully blind to a sustained smear campaign against Yim. Genser is Managing Director of Perseus Strategies, an international law firm. Over more than two decades, he
Ningbo FEED Meeting Confirms Full Confidence in Q1 2027 FID for Allied Biofuels’ US$6.1 Billion Presidential Decree-Backed SAF and e-SAF Project18.9.2026 17:38:00 CEST | Press release
Allied Biofuels has held a major Front-End Engineering Design (FEED) meeting at Sinopec’s office in Ningbo, China, bringing together Allied Biofuels, Sinopec Engineering Group Co., Ltd. of China, Topsoe A/S of Denmark, Sasol South Africa Limited, and Plug Power of the United States — the principal international engineering and technology providers supporting its US$6.1 billion Presidential Decree-backed Sustainable Aviation Fuel (SAF) and e-SAF project in Uzbekistan. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918708077/en/ FEED Meeting - Ningbo, China At the joint FEED meeting of the project’s core engineering and technology stakeholders, the discussions established clear alignment on engineering responsibilities, technology interfaces, design deliverables, project integration and the coordinated execution programme required to advance the project through FEED. All stakeholders working on the project expressed full co
Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli® (Relacorilant)18.9.2026 14:00:00 CEST | Press release
Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission (EC) should approve relacorilant, combined with the chemotherapy drug nab-paclitaxel, for the treatment of patients with platinum-resistant ovarian cancer. The CHMP’s recommendation is based on positive data from Corcept’s Phase 2 and pivotal Phase 3 ROSELLA trials, in which patients receiving relacorilant combined with nab-paclitaxel experienced improved progression-free and overall survival compared to patients who received nab-paclitaxel alone. The safety profile of relacorilant plus nab-paclitaxel in these trials was consistent with the safety profile of nab-paclitaxel monoth
Enhertu® Recommended for Approval in the EU by CHMP as Adjuvant Treatment for Patients with Residual Disease After Neoadjuvant Treatment for HER2 Positive Early Breast Cancer18.9.2026 14:00:00 CEST | Press release
Recommendation based on DESTINY-Breast05 phase 3 trial results that showed Enhertu reduced the risk of invasive disease recurrence or death by 53% versus T-DM1 Daiichi Sankyo and AstraZeneca’s Enhertu has the potential to become a new standard of care in this early breast cancer setting Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the adjuvant treatment of adult patients with resected HER2 positive breast cancer who have residual invasive disease after neoadjuvant taxane-based and HER2 targeted treatment. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the DESTINY-Breast05 phase 3 trial presented at th
CHMP Recommends EU Approval of New Indication for Alfasigma’s Jyseleca® (filgotinib), Treatment of Adults With Axial Spondyloarthritis18.9.2026 12:58:00 CEST | Press release
The information contained within this press release is for the purpose of scientific exchange.It is intended for scientific, financial and investor media only.If approved, Jyselecawill be indicated for the treatment of patients with active axial spondyloarthritis (axSpA), both non-radiographic and radiographic forms of the disease, who have responded inadequately to conventional therapy.Despite the availability of multiple treatment options, nearly half of people living with axSpA do not respond adequately to current therapies, and just 10-20% reach inactive disease within 16-24 weeks of initiating treatment.CHMP’s positive opinion is based on findings from the OLINGUITO Phase 3 study, where improvements in the signs and symptoms of axSpA with filgotinib were observed early and maintained over 52 weeks of treatment.Jyselecais already approved in Europe and the United Kingdom, for the treatment of moderate to severe rheumatoid arthritis and ulcerative colitis. Alfasigma S.p.A, a global
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom